Solasia Pharma K.K. reported consolidated earnings results for the nine months ended September 30, 2019. For the six months, the company reported revenue of JPY 291 million compared to JPY 110 million a year ago. Operating loss was JPY 1,585 million compared to JPY 1,538 million a year ago. Loss was JPY 1,672 million compared to JPY 1,533 million a year ago. Basic loss per share was JPY 15.93 compared to JPY 17.16 a year ago.

The company provided consolidated earnings guidance for the year ending December 31, 2019. For the year, the company expects net sales in the range of JPY 500 million to JPY 1,700 million, operating loss in the range of JPY 3,000 million to JPY 2,000 million, loss in the range of JPY 3,000 million to JPY 2,000 million and basic loss per share of JPY 28.54 to JPY 19.02.